137 related articles for article (PubMed ID: 38593446)
21. Cytotoxic chemotherapy for adrenocortical carcinoma.
Dogliotti L; Berruti A; Pia A; Paccotti P; Alì A; Angeli A
Minerva Endocrinol; 1995 Mar; 20(1):105-9. PubMed ID: 7544429
[TBL] [Abstract][Full Text] [Related]
22. Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma.
Heo YJ; Yoo JH; Choe YS; Park SH; Lee SB; Kim HA; Choi JY; Lee YA; Lim BC; Chueh HW
Ann Pediatr Endocrinol Metab; 2022 Sep; 27(3):236-241. PubMed ID: 34670067
[TBL] [Abstract][Full Text] [Related]
23. Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.
Arshad U; Taubert M; Kurlbaum M; Frechen S; Herterich S; Megerle F; Hamacher S; Fassnacht M; Fuhr U; Kroiss M
Eur J Endocrinol; 2018 Oct; 179(5):287-297. PubMed ID: 30087117
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic treatment of adrenocortical carcinoma.
Ahlman H; Khorram-Manesh A; Jansson S; Wängberg B; Nilsson O; Jacobsson CE; Lindstedt S
World J Surg; 2001 Jul; 25(7):927-33. PubMed ID: 11572034
[TBL] [Abstract][Full Text] [Related]
25. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
Sasaki S
Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Terzolo M; Fassnacht M; Perotti P; Libé R; Kastelan D; Lacroix A; Arlt W; Haak HR; Loli P; Decoudier B; Lasolle H; Quinkler M; Haissaguerre M; Chabre O; Caron P; Stigliano A; Giordano R; Zatelli MC; Bancos I; Fragoso MCBV; Canu L; Luconi M; Puglisi S; Basile V; Reimondo G; Kroiss M; Megerle F; Hahner S; Kimpel O; Dusek T; Nölting S; Bourdeau I; Chortis V; Ettaieb MH; Cosentini D; Grisanti S; Baudin E; Berchialla P; Bovis F; Sormani MP; Bruzzi P; Beuschlein F; Bertherat J; Berruti A
Lancet Diabetes Endocrinol; 2023 Oct; 11(10):720-730. PubMed ID: 37619579
[TBL] [Abstract][Full Text] [Related]
27. Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations.
Abrahamsson G; Ekerhovd E; Janson PO; Jansson S; Ahlman H; Wängberg B; Norström A
Acta Obstet Gynecol Scand; 2020 Oct; 99(10):1297-1302. PubMed ID: 32282928
[TBL] [Abstract][Full Text] [Related]
28. Clinical results of the use of mitotane for adrenocortical carcinoma.
Kasperlik-Zaluska AA
Braz J Med Biol Res; 2000 Oct; 33(10):1191-6. PubMed ID: 11004719
[TBL] [Abstract][Full Text] [Related]
29. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
[TBL] [Abstract][Full Text] [Related]
30. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
31. Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study.
Mormando M; Galiè E; Bianchini M; Lauretta R; Puliani G; Tanzilli A; Anceschi U; Simone G; Petreri G; Graziano G; Pace A; Appetecchia M
Front Oncol; 2023; 13():1222002. PubMed ID: 37645432
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
Germano A; Rapa I; Volante M; Lo Buono N; Carturan S; Berruti A; Terzolo M; Papotti M
Mol Cell Endocrinol; 2014 Jan; 382(1):1-7. PubMed ID: 24018612
[TBL] [Abstract][Full Text] [Related]
33. [A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP].
Yamashita D; Hanai T; Onuki T; Suzuki K; Nakayama T
Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):12-17. PubMed ID: 31956212
[TBL] [Abstract][Full Text] [Related]
34. Emerging drugs for adrenocortical carcinoma.
Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
[TBL] [Abstract][Full Text] [Related]
35. Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane.
Szkodziak PR; Czuczwar P; Woźniak S; Szkodziak F; Paszkowski T
Ginekol Pol; 2017; 88(10):576-577. PubMed ID: 29192420
[TBL] [Abstract][Full Text] [Related]
36. Albumin/Mitotane Interaction Affects Drug Activity in Adrenocortical Carcinoma Cells: Smoke and Mirrors on Mitotane Effect with Possible Implications for Patients' Management.
Schiavon A; Saba L; Catucci G; Petiti J; Puglisi S; Borin C; Reimondo G; Gilardi G; Giachino C; Terzolo M; Lo Iacono M
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069023
[TBL] [Abstract][Full Text] [Related]
37. Hypertriglyceridemia and its impact on mitotane monitoring in adrenocortical carcinoma.
Martens S; Lapauw B
Endocrinol Diabetes Metab Case Rep; 2023 Oct; 2023(4):. PubMed ID: 38056082
[TBL] [Abstract][Full Text] [Related]
38. Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma.
Altieri B; Kimpel O; Megerle F; Detomas M; Chifu I; Fuss CT; Quinkler M; Kroiss M; Fassnacht M
Eur J Endocrinol; 2024 Feb; 190(2):139-150. PubMed ID: 38244214
[TBL] [Abstract][Full Text] [Related]
39. Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors.
Vezzosi D; Do Cao C; Hescot S; Bertherat J; Haissaguerre M; Bongard V; Drui D; De La Fouchardière C; Illouz F; Borson-Chazot F; Djobo B; Berdelou A; Tabarin A; Schlumberger M; Briet C; Caron P; Leboulleux S; Libe R; Baudin E;
Horm Cancer; 2018 Feb; 9(1):62-69. PubMed ID: 29071575
[TBL] [Abstract][Full Text] [Related]
40. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.
Haak HR; Hermans J; van de Velde CJ; Lentjes EG; Goslings BM; Fleuren GJ; Krans HM
Br J Cancer; 1994 May; 69(5):947-51. PubMed ID: 8180029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
